Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

This study has been completed.

First Received on September 13, 2005. Last Updated on July 27, 2007 History of Changes

Sponsor:	West Penn Allegheny Health System
Collaborator:	Merck
Information provided by:	West Penn Allegheny Health System
ClinicalTrials.gov Identifier:	NCT00189475

Purpose

Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.

Condition	Intervention	Phase
Upper Respiratory Infection	Drug: Montelukast	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind
Official Title:	A Pilot Study to Evaluate the Potential of Montelukast to Prevent the Development of Nasal Symptomatology During Natural Viral Upper Respiratory Infections

Resource links provided by NLM:

MedlinePlus related topics: Common Cold

Drug Information available for: Montelukast sodium Montelukast

U.S. FDA Resources

Further study details as provided by West Penn Allegheny Health System:

Detailed Description:

This is a randomized double-blinded placebo controlled trial to assess the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years. All subjects complete daily assessments of cold symptoms, nasal clearance rates and secretion rates during each day of the study. Phlebotomy is performed once for the determination of cytokine genotyping and allergy skin testing is performed once for the assessment of atopy.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adults 18 to 50 years of age.
Male or female, who are not pregnant or lactating.
Common cold symptoms for less than 24 hours.
At least 2 of the following 9 symptoms: cough, headache, hoarseness, muscle ache, nasal drainage, nasal congestion, scratch throat, sneezing and malaise.

Exclusion Criteria:

Investigational medication in past 30 days.
Known hypersensitivity to any ingredients in study medication.
History of asthma or other chronic diseases.
Females of childbearing potential who are not using a medically acceptable form of birth control.
Patients with nasal ulcers within the past 1 month, nasal surgery within the past 6 months, nasal trauma within the past 2 months or presence of nasal polyps or nasal deformities causing significant nasal obstruction.
Females with a positive urinary HCG test.
Patients with a positive rapid antigen test for streptococcal infection.
Common cold symptoms for more than 24 hours.
Patients who are users of illicit drugs.
Patients who are on rifampin or phenobarbital.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00189475

Locations

United States, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212

Sponsors and Collaborators

West Penn Allegheny Health System

Merck

Investigators

Principal Investigator:

Deborah Gentile, MD

West Penn Allegheny Health System

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00189475 History of Changes
Other Study ID Numbers:	RC - 3559
Study First Received:	September 13, 2005
Last Updated:	July 27, 2007
Health Authority:	United States: Institutional Review Board

Keywords provided by West Penn Allegheny Health System:

Cold
Upper Respiratory Infection

Additional relevant MeSH terms:

Common Cold
Respiratory Tract Infections
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases
Infection
Montelukast

Leukotriene Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012